Josep Castellví Vives Institutions of which they are part Senior researcher Translational Molecular Pathology Vall Hebron Institut de Recerca Email Josep Castellví Vives Email Institutions of which they are part Senior researcher Translational Molecular Pathology Vall Hebron Institut de Recerca
Research lines Study of CAP-dependent and CAP-independent signalling pathways in breast carcinomas. In previous works we studied several factors involved in cell signalling pathways that control cell growth. The found that the phosphorylated form of 4E-BP1 was the only factor that correlated with prognosis, and histologic aggressive features in several types of cancers. 4E-BP1 is a key regulator of CAP-dependent traslation and its main function is the inactivation of eIF4E. However, not all the aggressive tumors show activation of this factor. On the other hand, it has been shown that under hypoxia conditions cells the translation of some key factors can be regulated by CAP-independent pathways, mediated by factors known as ITAFs. The aim of our study is to find the CAP-depdendent/CAP-independent balance in tumors in relation to hypoxia, and evaluate its impact on prognosis. IP: Josep Castellví Vives Projects Overcomming chemoresistance in HNSCC IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Yoelsis Garcia Mayea, David Virós Porcuna, Josep Castellví Vives, María Garrido Martínez, Pablo Verges Fort, Marina Bataller Fernández Funding agency: Fundación hna Funding: 50000 Reference: FUND.HNA/PREMI/LLEONART/2025 Duration: 01/10/2025 - 30/09/2027 Establecimiento de una estrategia combinada en carcinoma escamoso de cabeza y cuello (HNSCC): una herramienta eficaz para superar los tumores quimiorresistentes. IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Yoelsis Garcia Mayea, Juan Lorente Guerrero, Juan Fernando Fuentes Cabrera, Sergio Benavente Norza, Josep Castellví Vives, Marina Bataller Fernández Funding agency: Instituto de Salud Carlos III Funding: 240000 Reference: PI24/00630 Duration: 01/01/2025 - 31/12/2027 Nanocápsulas que combinan nuevos fármacos con quimioterapia convencional para curar cánceres resistentes IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Irene Braña Garcia, Yoelsis Garcia Mayea, David Virós Porcuna, Juan Fernando Fuentes Cabrera, Josep Castellví Vives, Marina Bataller Fernández Funding agency: Instituto de Salud Carlos III Funding: 318750 Reference: AC24/00057 Duration: 01/01/2025 - 31/12/2027 Precision Endometriosis Research: Integrating Molecular Classification, In Vitro Modeling, and Personalized Therapeutic Strategies IP: Eva Colas Ortega Collaborators: Elena Suarez Salvador, Francesc Xavier Serra Marin, Carina Masferrer Ferragutcasas, Anna Ruano Lopez, Josep Castellví Vives, Sonia Monreal Clua, Diana Alejandra Guerrero Lojano, Raquel Delgado Gil Funding agency: Fundació La Marató de TV3 Funding: 200000 Reference: 202407-10 Duration: 20/02/2025 - 19/02/2028 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 … Next page › Last page »
